COR
Cencora, Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted diluted EPS non-GAAP | $4.75 | Q2 FY2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Distribution — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COR
this stock
Cencora, Inc.
|
$59.04B | -10.0% | +9.3% | 23.3 | 2.8% |
|
MCK
Mckesson Corp
|
$96.88B | -1.7% | +3.1% | 21.0 | 3.4% |
|
CAH
Cardinal Health Inc
|
$55.49B | +15.3% | -1.9% | — | 3.0% |
|
HSIC
Henry Schein Inc
|
$9.61B | +11.7% | +5.9% | 25.5 | 6.3% |
|
EBOSY
EBOS Group Limited/ADR
|
$2.67B | -24.4% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COR | +2.3% | +7.9% | -14.5% | +7.2% | -10.0% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +1.0% | +3.8% | -23.5% | +6.1% | -20.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.